蛋白二硫键异构酶家族抑制剂用于多发性骨髓瘤治疗
多发性骨髓瘤对细胞蛋白稳态紊乱高度敏感,蛋白酶体抑制剂初始有效但耐药限制缓解持久性。筛选发现E61可增强多种蛋白酶体抑制剂活性,其靶点为蛋白二硫键异构酶家族成员;化学优化获得茚类泛PDI抑制剂E64FC26,在骨髓瘤小鼠中改善生存并增强硼替佐米活性且无不良反应。
要点
- E61是多种蛋白酶体抑制剂的强效增强剂,对多发性骨髓瘤具有特异性活性。
- E61的分子靶点为蛋白二硫键异构酶家族多个成员。
- 先导化合物E64FC26在骨髓瘤小鼠中改善生存并增强硼替佐米活性,无不良反应。
核心结论
- E64FC26作为早期药物候选物具有潜力,靶向多个PDI亚型是治疗难治性多发性骨髓瘤及相关疾病的策略。
研究设计与样本
- 研究对多个化学文库进行筛选以寻找蛋白酶体抑制剂再敏化化合物,并开展小鼠多发性骨髓瘤实验。
主要发现
- 筛选鉴定出E61为多种蛋白酶体抑制剂的强效增强剂,对多发性骨髓瘤具有特异性活性。
- 采用点击化学与肽质量指纹图谱串联方法,鉴定出多个蛋白二硫键异构酶家族成员为E61的主要分子靶点。
- E61处理诱导强烈的内质网应激和氧化应激反应以及泛素化蛋白积累。
- 化学优化获得以先导化合物E64FC26为代表的茚类新结构类别,为高活性的泛PDI抑制剂。
- 在骨髓瘤小鼠中,E64FC26改善生存并增强硼替佐米活性,且无任何不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple Myeloma (MM) is highly sensitive to disruptions in cellular protein homeostasis. Proteasome inhibitors (PIs) are initially effective in the treatment of MM, although cures are not achievable and the emergence of resistance limits the durability of responses. New therapies are needed for refractory patients, and those that combat resistance to standard of care agents would be particularly valuable. Screening of multiple chemical libraries for PI re-sensitizing compounds identified E61 as a potent enhancer of multiple PIs and MM specific activity. Using a tandem approach of click chemistry and peptide mass fingerprinting, we identified multiple protein disulfide isomerase (PDI) family members as the primary molecular targets of E61. PDIs mediate oxidative protein folding, and E61 treatment induced robust ER and oxidative stress responses as well as the accumulation of ubiquitinylated proteins. A chemical optimization program led to a new structural class of indene (exemplified by lead E64FC26), which are highly potent pan-style inhibitors of PDIs. In mice with MM, E64FC26 improved survival and enhanced the activity of bortezomib without any adverse effects. This work demonstrates the potential of E64FC26 as an early drug candidate and the strategy of targeting multiple PDI isoforms for the treatment of refractory MM and beyond.
引用
- Robinson RM, Reyes L, Duncan RM, et al. Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma. Leukemia. 2018. PMID: 30315229. doi:10.1038/s41375-018-0263-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。